MDxHealth Announces Global Rights to Market Philips’ Prostate Cancer Prognostic Test

MDxHealth Announces Global Rights to Market Philips’ Prostate Cancer Prognostic Test
MDxHealth recently signed an agreement that gives it the worldwide licensing rights to manufacture and market its prostate cancer prognostic test that uses Philips' recently validated biomarker PDE4D7. MDxHealth will start preparing for the launch of its InformMDx  prognostic test, which will help evaluate a patient's risk of disease worsening and development of secondary tumors. "This is an exciting deal, which moves us a step closer towards launching InformMDx, our fourth commercial test which
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *